文献速递心力衰竭与心肌病

恩格列净对心力衰竭患者肺动脉压的影响:EMBRACE-HF试验结果

Empagliflozin Effects on Pulmonary Artery Pressure in Patients With Heart Failure: Results From the EMBRACE-HF Trial.
PubMed 文献 · Circulation · 2021-02-08

EMBRACE-HF是一项随机、双盲、安慰剂对照试验,纳入65例植入肺动脉压力传感器的心衰患者,比较恩格列净10 mg每日一次与安慰剂的疗效。结果显示,恩格列净显著降低肺动脉舒张压,8-12周平均降低1.5 mm Hg,12周降低1.7 mm Hg,且不依赖于袢利尿剂管理。

要点

  • 恩格列净降低肺动脉舒张压,8-12周平均降低1.5 mm Hg。
  • 降压效果自第1周出现并随时间增强,12周降低1.7 mm Hg。
  • 效果独立于袢利尿剂使用,未影响健康状态等次要终点。

核心结论

  • 在植入CardioMEMS肺动脉压力传感器的心衰患者中,恩格列净快速降低肺动脉压力,效果随时间增强,且似乎独立于袢利尿剂管理。

主要发现

  • 恩格列净组平均肺动脉舒张压(8-12周)较安慰剂组低1.5 mm Hg(95%CI 0.2-2.8;P=0.02),第12周低1.7 mm Hg(95%CI 0.3-3.2;P=0.02)。
  • 肺动脉收缩压和平均压结果一致。
  • 两组袢利尿剂日均呋塞米等效剂量无差异,堪萨斯城心肌病问卷评分、利钠肽水平和6分钟步行距离无显著差异。

临床怎么用

  • 对于植入肺动脉压力传感器的心衰患者,恩格列净可快速降低肺动脉压力,且不依赖于袢利尿剂调整,但需结合指南和患者具体情况使用。

局限性

  • 样本量较小(65例),随访时间短(12周),主要终点为肺动脉压力替代指标,硬终点证据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sodium glucose cotransporter 2 inhibitors (SGLT2 inhibitors) prevent heart failure (HF) hospitalizations in patients with type 2 diabetes and improve outcomes in those with HF and reduced ejection fraction, regardless of type 2 diabetes. Mechanisms of HF benefits remain unclear, and the effects of SGLT2 inhibitor on hemodynamics (filling pressures) are not known. The EMBRACE-HF trial (Empagliflozin Evaluation by Measuring Impact on Hemodynamics in Patients With Heart Failure) was designed to address this knowledge gap. METHODS: EMBRACE-HF is an investigator-initiated, randomized, multicenter, double-blind, placebo-controlled trial. From July 2017 to November 2019, patients with HF (regardless of ejection fraction, with or without type 2 diabetes) and previously implanted pulmonary artery (PA) pressure sensor (CardioMEMS) were randomized across 10 US centers to empagliflozin 10 mg daily or placebo and treated for 12 weeks. The primary end point was change in PA diastolic pressure (PADP) from baseline to end of treatment (average PADP weeks 8-12). Secondary end points included health status (Kansas City Cardiomyopathy Questionnaire score), natriuretic peptides, and 6-min walking distance. RESULTS: Overall, 93 patients were screened, and 65 were randomized (33 to empagliflozin, 32 to placebo). The mean age was 66 years; 63% were male; 52% had type 2 diabetes; 54% were in New York Heart Association class III/IV; mean ejection fraction was 44%; median NT-proBNP (N-terminal pro B-type natriuretic peptide) was 637 pg/mL; and mean PADP was 22 mm Hg. Empagliflozin significantly reduced PADP, with effects that began at week 1 and amplified over time; average PADP (weeks 8-12) was 1.5 mm Hg lower (95% CI, 0.2-2.8; P=0.02); and at week 12, PADP was 1.7 mm Hg lower (95% CI, 0.3-3.2; P=0.02) with empagliflozin versus placebo. Results were consistent for PA systolic and PA mean pressures. There was no difference in mean loop diuretic management (daily furosemide equivalents) between treatment groups. No significant differences between treatment groups were observed in Kansas City Cardiomyopathy Questionnaire scores, natriuretic peptide levels, and 6-min walking distance. CONCLUSIONS: In patients with HF and CardioMEMS PA pressure sensor, empagliflozin produced rapid reductions in PA pressures that were amplified over time and appeared to be independent of loop diuretic management. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03030222.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Nassif ME, Qintar M, Windsor SL, et al. Empagliflozin Effects on Pulmonary Artery Pressure in Patients With Heart Failure: Results From the EMBRACE-HF Trial. Circulation. 2021. PMID: 33550815. doi:10.1161/CIRCULATIONAHA.120.052503

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。